A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality

This study has suspended participant recruitment.
Sponsor:
Collaborator:
Ben-Gurion University of the Negev
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00569413
First received: December 6, 2007
Last updated: June 9, 2010
Last verified: June 2010

December 6, 2007
June 9, 2010
April 2011
October 2011   (final data collection date for primary outcome measure)
Brain Imaging data of DRD2 receptor occupancy during watching a sex videotape and neutral videotape [ Time Frame: 2 Brain imaging sessions a week apart ] [ Designated as safety issue: Yes ]
Brain Imaging data of DRD2 receptor occupancy during watching a sex videotape a and neutral videotape [ Time Frame: 2 Brain imaging sessions a week apart ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00569413 on ClinicalTrials.gov Archive Site
Questionnaire ratings of human sexuality, pleasure, and anticipatory reward [ Time Frame: Taken during brain scans ] [ Designated as safety issue: No ]
Questionnaire ratings of human sexuality, pleasure and anticipatory reward [ Time Frame: Taken during brain scans ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality
A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality

The current study combines a molecular genetic perspective, self report and brain imaging to the study of human sexuality in control subjects and individuals from a sexual disorder clinic. The investigators hypothesize that the variability in components of the brain dopaminergic system expressed in the mesolimbic reward system can explain variability in human sexuality, especially in desire and pleasure associated with sex.

We intend to combine molecular genetics of the dopamine receptors (D2, D3 D4 and D5) and brain imaging using 11 C Raclopride in Positron Emission Tomography (PET). 11 C Raclopride is a ligand which binds to the dopamine receptor D2 and can measure dopamine release during pleasure or anticipatory reward associated with sex. The current proposal will measure changes in DRD2 receptor occupancy using 11 C Raclopride following explicit visual sexual desire cues in healthy control subjects and individuals who suffer from sexual dysfunction. This is in order to determine how individual genotypes modulate dopamine release in vivo in the human brain.

Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

A group of healthy volunteers from the general public. A group of patients who suffer from sexual disorder from a primary care clinic.

  • Hypoactive Sexual Desire Disorder
  • Erectile Dysfunction
Not Provided
  • 1
    Healthy control subjects (n=20) age 21-65 who do not suffer from a psychiatric diagnosis or neurological damage, are under age, or are pregnant women
  • 2
    20 patients who suffer from sexual disorder (reduced sexual desire or sexual function) from a sexual disorder clinic, age 21-65, without any other psychiatric disorder, neurological damage, are not under age or pregnant women.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Suspended
40
October 2011
October 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy volunteers and patients
  • Age 21-65
  • Male or female

Exclusion Criteria:

  • Psychiatric diagnosis/psychosis
  • Neurological damage associated with loss of consciousness
  • Infectious disease HIV
  • Herpes
  • Syphilis
  • Hyperactivity treated with ritalin
  • Pregnant women
  • Under age
Both
21 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00569413
281207HMO-CTIL, First 978[1].07
Yes
Prof. Roland Chisin, Hadassah Medical Organization
Hadassah Medical Organization
Ben-Gurion University of the Negev
Principal Investigator: Aviv M Weinstein, Ph.D Hadasah Medical Organization, Jerusalem Israel
Hadassah Medical Organization
June 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP